Medicis Pharmaceutial News

Seattle-based attorney Anne Bremner said the Sheriff's Department and District Attorney's Office have turned down similar requests she submitted, paving the way for the official request to the attorney general.

Medicis Pharmaceutical Corp., a maker of wrinkle treatments and acne drugs, was sued by Revance Therapeutics Inc.

Medicis gains on positive comments out of Goldman earlier today. The firm says the company is one of the most likely M&A targets in its peer group, and notes that its growth potential is under appreciated.

Shares of Obagi Medical Products rose 4.69% on Monday to $12.95 +0.58 and traded as high as $13.15 after being mentioned as a possible acquisition candidate for the second time in as many weeks.

The issue had an original size of USD400m that was increased by USD50m following the full exercise of the over-allotment option granted by the company to the underwriters.

SCOTTSDALE, Ariz., May 10, 2012 -- Medicis today announced that it intends, subject to market and other conditions, to offer $400 million aggregate principal amount of convertible senior notes due 2017 in an offering registered under the Securities Act of 1933, as amended .

On Tuesday, Medicis Pharmaceuticals Corporation Class A reported its first quarter earnings and discussed the following topics in its earnings conference call.

MRX has been the subject of a number of other recent research reports. Analysts at Goldman Sachs raised their price target on shares of Medicis Pharmaceutic to $44.00 in a research note to investors on Thursday, April 26th.

Shares of the following companies may have unusual moves in U.S. trading tomorrow.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia SCOTTSDALE, Ariz., May 3, 2012 -- Medicis today announced that the Company expects to report 2012 first quarter financial results after the market closes on Tuesday, May 8, ... (more)